^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Colorectal Cancer
    Drug:iparomlimab (QL1604) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors

    Excerpt:
    ...Histologically confirmed locally advanced or metastatic dMMR or MSI-H status colorectal carcinoma or other malignant solid tumors; 4....
    Trial ID:
    NCT04326829
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO Asia 2023
    Title:

    105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors

    Published date:
    11/27/2023
    Excerpt:
    From Jun 19, 2020 to Jan 12, 2023, 120 pts with dMMR/MSI-H solid tumors were enrolled, of whom 80 (66.7%) pts had colorectal cancer (CRC), 18 (15.0%) pts had gastric cancer, and 22 (18.3%) had other solid tumors….In the CRC subgroup, the ORR and DCR per IRRC were 34/80 (42.5%, 95% CI: 31.5%–54.1%) and 62/80 (77.5%, 95% CI: 66.8%–86.1%), respectively.
    Trial ID:
    NCT04326829